Clinical Study Synopsis
|
|
- Moris Curtis
- 5 years ago
- Views:
Transcription
1 Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labeling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.
2 Study Sponsor: Study Number: CC Study Phase: Official Study Title: Clinical Trial Results Synopsis Study Design Description Bayer Healthcare Pharmaceuticals Inc N/A Therapeutic Area: Analgesics NCT Single dose methodology pilot study comparing the safety and efficacy of naproxen, ibuprofen and placebo in treatment of pain secondary to dental impaction surgery Test Product Name of Test Product: Name of Active Ingredient: Dose and Mode of Administration: Aleve (Naproxen, BAYH6689), mg Naproxen Single dose of Naproxen mg (NAP 187.5) capsule, orally with 4 ounces of water Reference Therapy/ Reference Therapy: Ibuprofen 200 mg Matching Dose and Mode of Administration: Duration of Treatment: Upto 8 hours Single dose of ibuprofen 200 mg (IBU 200) or matching placebo capsule, orally with 4 ounces of water Studied period: Date of first subjects first visit: Dec 1990 Date of last subjects last visit: Apr 1991 Study Center(s): One investigational site treated 81 subjects at one center located in USA Methodology: This single center, single-dose, randomized, double-blind, parallel and placebo- and active- controlled study was designed for 75 evaluable subjects. Subjects were randomly assigned to one of the 3 treatment groups (placebo, naproxen or ibuprofen). Pain response was evaluated immediately prior to administration of study drug, one hour after administration and hourly thereafter up to 8 hours. Pain intensity and pain relief were measured on categorical scales and subjects were asked if their pain was at least half gone from baseline at each time point. Subjects remained in the study for up to 8 hours. Back up analgesic medications was available for those subjects who experienced insufficient pain relief from the study medication. At the post-operative follow-up evaluation, the subjects self-rating records were reviewed. Indication/ Main Inclusion Criteria: Subjects at least 15 years of age, with at least moderate post operative pain following surgical removal of one or 2 third molars on the same side of the mouth (atleast one of which was partial bony or complete bony impaction) were included in the study. Page 1 of 4
3 Study Objectives: Evaluation Criteria: Statistical Methods: Overall: To determine the relative analgesic efficacy and adverse effect liability of single oral doses of naproxen compared to ibuprofen and placebo in the treatment of postoperative dental pain following the surgical removal of one or 2 impacted third molars. In addition, results from this study were used to determine the feasibility and sample size for a potential future definitive study or studies. Efficacy (Primary): The primary efficacy variables were obtained by computing the summed pain intensity difference (SPID) scores on the categorical scale and total pain relief (TOTPAR) scores for each subject over the entire 8-hours study period. Efficacy (Secondary): -SPID and TOTPAR scores: 4- and 6-hour scores. -Peak PID: Maximum PID score on the categorical scale. -Peak relief: Maximum pain relief score. -Pain half gone: Proportion of time points at which pain was reported as half gone. -Relief onset: Time at which the subject first reported at least "some" pain relief -Global evaluation: The "end-of-study" overall evaluation. -Use of backup medication: Time at which the subject used backup medication. Safety: Safety was evaluated based on adverse events observed by study personnel or reported by the subjects. Efficacy (Primary): Continuous efficacy variables were analyzed by applying a one way analysis of variance (ANOVA) model with treatment as the main effect and with two-tailed least significant-difference tests being performed for pairwise comparisons. Efficacy (Secondary): Secondary efficacy variables were analyzed using analysis of variance, with the exception of the time related variables. The generalized Wilcoxon test was used to compare the three treatment groups for the two time related-variables, time to taking backup medication and time to relief onset. Safety: All reported adverse events were analyzed by treatment group and summarized by the number of subjects reporting adverse events, severity, relationship to study drug and body system. Likelihood ratio chi-square tests were used to compare the numbers of subjects in each treatment group reporting one or more adverse event. Number of Subjects: Out of the 88 subjects enrolled in the study, 81 subjects were randomized. Eighty subjects were included in the safety analysis since one subject was lost to follow up. Three of the 80 subjects were Page 2 of 4
4 excluded for the efficacy analysis since one subject missed more than one evaluation point, one more subject was excluded due to a protocol violation and one subject had consumed an analgesic on the study day. Study Results Results Summary Subject Disposition and Baseline A total of 88 subjects were enrolled in the study, out of which 81 subjects were randomized into one of the 3 study groups (NAP 187.5, IBU 200 or ). Out of the 81 subjects, all except one subject (lost to follow up) were included in the safety analysis. A total of 77 subjects out of the 80 subjects were included in the efficacy analysis; 26 subjects received naproxen, 25 received ibuprofen and 26 subjects received placebo. Out of the 81 randomized subjects, 21 subjects completed the study (8 subjects each in NAP and IBU 200 groups and 5 subjects in the placebo group). A total of 60 subjects withdrew prematurely from the study. One of the subjects was lost to follow up, 2 subjects due to the noncompliance with the protocol, one subject due to inappropriate enrollment and 56 subjects withdrew from the study due to the need of backup medications (18 in NAP 187.5, 17 in IBU 200 and 21 in placebo). The 3 treatment groups were similar in terms of baseline demographic parameters. Subjects ranged from 17 to 39 years in age (mean: 24.7 years). There were more females than males in the study (56% versus 44%). Most (84%) of the subjects were Caucasian. Subjects weighed between 90 pounds and 250 pounds (mean: pounds). Fourteen (18%) subjects had one tooth extracted, 61(79%) had 2 teeth extracted and 2 (3%) had 3 teeth extracted. Sixty seven (87%) of the subjects had one impacted tooth extraction and 10 (13%) had 2 impacted teeth extraction. The time between surgery and the first dose of study medication ranged from 12 minutes to slightly over 4 hours (mean: 1.6 hours). Moderate pain was reported by 74 (96%) subjects at baseline, and 3 (4%) reported severe pain. Results Summary Efficacy IBU 200 appeared to have slightly higher (better) analgesic responses than NAP for most of the derived efficacy measures, however no statistically significant difference was observed in any of the efficacy parameters among the 3 treatment groups. In general, trends favored the two active treatments over placebo. The only primary efficacy variable with a statistically significant overall treatment effect was the 4-hour SPID score. For 4-hour SPID, IBU 200 was significantly superior to placebo (p=0.010). The 6- and 8-hour SPIDs did not have significant overall treatment effects but the LSD multiple comparison procedure showed that IBU 200 demonstrated significantly better analgesia than placebo (p=0.021 for 6-hour SPID and p=0.044 for 8-hour SPID). No significant differences were found between NAP and placebo for any of the efficacy variables analyzed. No significant differences between NAP and IBU 200 were observed at any hourly evaluation for either PID or relief, but IBU 200 was found to be significantly superior to placebo for PID at 2, 3 and 4 hours after dosing and for relief at 2 hours after dosing. No significant differences (p=0.167) were detected among the 3 treatment groups in the subjects overall global rating of the treatment. No statistically significant (p 0.278) differences among the 3 treatment groups was observed for the time to relief onset. Forty six percent of the subjects in the placebo group experienced 'some' pain relief during the study and more than 50% of the subjects in both NAP and IBU 200 experienced 'some' relief within 2 hours of the drug administration. No statistically significant differences (p 0.246) among the 3 treatment groups was observed for backup medication usage. More than 75% of the subjects in the placebo group required backup medication. About 50% of the subjects in the NAP and IBU 200 groups took Page 3 of 4
5 backup medication within 4 hours after dosing and less than 75% of them needed backup medication throughout the 8-hour study period. Table1: Eight-Hour Efficacy Analysis (N=77) N=26 N=26 N=25 Variable Mean SD Mean SD Mean SD P-Value 8 hr SPID (Cat) hr TOTPAR SPID: Summed Pain Intensity Difference; TOTPAR: Total Pain Relief; hr: Hour ;Cat: Categorical Results Summary Safety Twelve (15%) of the 80 subjects reported a total of 17 adverse events. Two of 27 (7%) subjects in the placebo group reported 2 adverse events, 5 of 27 (19%) in NAP reported 8 adverse events, 5 of 26 (19%) in IBU 200 reported 7 adverse events. The adverse events typically consisted of somnolence, headache, or nausea. All the events were recorded as 'mild' (85%) except 2 (12%) events (asthenia in IBU 200 and somnolence in NAP 187.5) which were graded to be 'moderate' in severity). None of adverse events were severe. Four of the total 17 adverse events (24%) was considered "probably not related to the study medication", 11 of the 17 (65%) was recorded as "unknown" in terms of the relation to the study drug and 2 of the 17 (11%) (dry mouth in and asthenia in IBU 200) were considered "probably related to the study drug". Conclusion(s) In this study, there were no statistically significant differences between NAP mg and IBU 200 mg for any of the derived efficacy measures. The ranks for the three treatment groups in order of more favorable analgesic responses were as follows IBU 200>NAP 187.5>placebo. The same order of groups (IBU 200>NAP 187.5> placebo) was observed for relief onset time and remedication time. Based on these results, it was concluded that hundreds of subjects would be needed to separate the two active treatments because of the small difference in analgesic response observed between these two groups. No further definitive study was recommended. Date Created or Date Last Updated: 07 Sep 2011 Page 4 of 4
Clinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A phase III comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationWebposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationA French, multicentre, placebo-controlled, randomised, double-blind,
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationStatistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue
STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationThis was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. NAME OF SPONSOR/COMPANY: Genzyme Corporation,
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Study Synopsis for Public Disclosure
Clinical Study Synopsis for Public Disclosure These results are supplied for informational purposes only in the interest of scientific disclosure. The synopsis may include approved and non-approved uses,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical
More informationClinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013
1. Clinical Study Report RANDOMIZED, OPEN, PARALLEL GROUP, PHASE IIIB STUDY ON THE EVALUATION OF EFFICACY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY IN PAEDIATRIC PATIENTS WITH ATOPIC DERMATITIS, WITH OR WITHOUT
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationParacetamol (acetaminophen) is a non-opioid analgesic with. analgesia RESEARCH
Pain control with paracetamol from a sustained release formulation and a standard release formulation after third molar surgery: a randomised controlled trial P Coulthard, 1 C M Hill, 2 J W Frame, 3 H
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information090177e182b31c5d\0.1\Draft\Versioned On:16-Dec :12
MAH: / Product: IBU/PSE Protocol Number EudraCT number (if applicable) Trial report number PMID / D.O.I. (if applicable) Date of trial Is the trial Trial design Background for conducting the trial Participants
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00671398 Title of Study: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationScottish Medicines Consortium
Scottish Medicines Consortium fentanyl 50 micrograms / dose, 100 micrograms/dose, 200 micrograms / dose nasal spray (Instanyl ) No. (579/09) Nycomed UK Ltd 09 October 2009 The Scottish Medicines Consortium
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationEvidenced Based Analgesic Efficacy in Post-Surgical Dental Pain
Evidenced Based Analgesic Efficacy in Post-Surgical Dental Pain Elliot V Hersh DMD, MS, PhD Professor Oral Surgery and Pharmacology University of Pennsylvania School of Dental Medicine Chair IRB#3, Office
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More information